CC40.8 is a broadly neutralizing antibody (bnAb) that targets the conserved S2 stem helix of β-coronavirus spike proteins. It exhibits broad reactivity against human β-CoVs and provides in vivo protection against SARS-CoV-2 infection in animal models, reducing weight loss and lung viral titers. CC40.8 offers a valuable template for developing pan-β-CoV vaccines.
Species reactivity
Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Applications
Neutralization
Host species
Human
Isotype
IgG1, kappa
Clone ID
CC40.8
Clonality
Monoclonal
Target
S2 Protein, Spike protein S2, Spike protein S2', Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, S
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Caption
SEC-HPLC detection for InVivoMAb Anti-SARS-CoV-2 S2 Protein Antibody (CC40.8).,Detects recombinant SARS-CoV-2 S2/Spike S2 (ECD) (Catalog No.:TD-VK749032) in indirect ELISA | SDS-PAGE for InVivoMAb Anti-SARS-CoV-2 S2 Protein Antibody (CC40.8). | Western blot analysis was performed using anti-SARS-CoV-2 S2 monoclonal antibody at 1ug/mL on various samples.Lane 1:recombinant SARS-CoV-2 S2/Spike S2 (ECD) (Catalog No.:TD-VK749032)Lane 2:negative control
Note
For research use only. Not suitable for clinical or therapeutic use.
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询